Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Craven House Capital (CRV)

Price $0.145 on 27-09-2023 at 16:30:02
Change $0.00 0%
Buy $0.17
Sell $0.12
Buy / Sell CRV Shares
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: -
Day's Volume: 0
Last Close: $0.145
Open: $0.145
ISIN: GB00BD4FQ360
Day's Range $0.145 - $0.145
52wk Range: $0.07 - $0.575
Market Capitalisation: $560k
VWAP: $0.00
Shares in Issue: 4m

Sector: Brokerage Services

Listed In: FTSE AIM All-Share,

Recent Trades History Craven House Capital (CRV)
Buy/Sell Volume Trade Prc Trade Type Trade Time

Share Price History for Craven House Capital
Time period:
to
Date Open High Low Close Volume

Share News for Craven House Capital

Craven House investee buys shareholding in Hemcheck Sweden

29th Aug 2023 14:34

(Alliance News) - Craven House Capital PLC on Tuesday noted that its investee Bio Vitos Medical Ltd is set to own 88% of medical technology company Hemcheck Sweden AB, after receiving conditional approval from Nasdaq Stockholm. Read More

IN BRIEF: Craven House investee buy by Hemcheck not approved by Nasdaq

3rd Jul 2023 14:33

Craven House Capital PLC - London-based investment fund with minority shareholding in four Swedish-managed eCommerce and pharmaceutical businesses - Notes planned acquisition of investee Bio Vitos by Hemcheck Sweden AB is not approved by Nasdaq. Bio Vitos enter into an agreement that will enable operations to continue, while Hemcheck is in the process of submitting an updated application to Nasdaq. "Bio Vitos anticipates that it will receive its shares in Hemcheck before the end of July 2023 which will be passed directly onto the Bio Vitos shareholders, which include Craven House," Craven says. Craven House has a 24.5% sake in Bio Vitos, a company that sells omega 3 tablets. Hemcheck is a company focused on detecting hemolyzed blood samples. Hemolyzed means red blood cells in a sample burst, usually rendering it unable to yield a test result. Read More

TRADING UPDATES: i-nexus to deliver growth; Craven House loss narrows

27th Feb 2023 19:42

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

IN BRIEF: Craven House Capital notes Bio Vitos buys Hemcheck majority

8th Feb 2023 14:35

Craven House Capital PLC - London-based investment fund with minority shareholding in four Swedish-managed eCommerce and pharmaceutical businesses - Says Bio Vitos, a company that sells omega 3 tablets and in which Craven House owns a 24.5% stake, enters into an agreement to buy an 88% stake in Hemcheck Sweden AB, a company focused on detecting hemolyzed blood samples. Hemolyzed means red blood cells in a sample burst, usually rendering it unable to yield a test result. Bio Vitos will pay Hemcheck SEK5.2 million, around GBP407,249, in cash for business and assets. Read More

Craven House Capital loss narrows, portfolio valuations unchanged

29th Nov 2022 14:26

(Alliance News) - Craven House Capital PLC said on Tuesday that its annual loss narrowed while the valuations of its four portfolio valuations remained unchanged. Read More

FTSE 100 Latest
Value7,593.22
Change-32.50

Login to your account

Forgot Password?

Not Registered